Navigation Links
Anadys Highlights ANA773 Data to be Presented at ASCO
Date:5/25/2011

advanced solid tumors were treated with ANA773 every-other-day (QOD) for 14 days, followed by a 14 day rest period, on continuous 28 day cycles.  20 patients participated in the study and were treated at dose levels of either 50mg, 100mg, 200mg, 400mg or 800mg (all QOD), with a minimum of three patients enrolled at each dose level. The endpoints for the study included safety, pharmacokinetics, biomarkers of immune activation and preliminary assessment of tumor response by RECIST.  

Next Steps for ANA773 Development

Anadys is advancing development of ANA773 in a separate indication, chronic hepatitis C virus infection, or HCV.  Anadys is currently preparing for a Phase IIa study of ANA773 in combination with ribavirin in HCV patients, which it expects to initiate in Europe this quarter.  The Company expects to receive 28-day data from the Phase IIa HCV study during the fourth quarter of this year.

About TLR7 agonists in cancer therapy

The potential benefits of the TLR7 mechanism in cancer therapy arise from the fundamental role of this receptor in immune activation.  The host immune system, once activated, plays an essential role in controlling the ability of cancer cells to grow, invade and metastasize.  Immunotherapy has had some success in treating selected tumors, and the potential to harness the immune system as a therapeutic modality remains of great interest to many oncologists.

TLR7 agonists are of particular interest because there is precedent for their use in cancer. Small molecule ligands for this receptor have been identified, including topical imiquimod (Aldara®) which is approved for the treatment of basal cell carcinoma in the United States. Imiquimod and other TLR7 agonists have also demonstrated early clinical activity against other tumor types, including melanoma and chronic lymphocytic leukemia. 

About Anadys

Anadys
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Report Third Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
3. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
4. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
5. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
6. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
7. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
8. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
10. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
11. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Boston, MA, San Antonio, TX (PRWEB) August 29, ... audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® ... it has been awarded an international Phase II ... patients with non-Hodgkin’s lymphoma. , Throughout this trial, ... services including, but not limited to, protocol and ...
(Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., a ... food processing industry, is asking industry professionals to prepare ... of the E2 soap they’re currently using to the ... . Hand hygiene is critical to fighting cross-contamination ... environment. Six key criteria are identified to evaluate the ...
(Date:8/28/2014)... August 28, 2014 “This kit has an ... screen from 0 to 150 ppb,” said Mark Tess, PhD, ... significant benefit to plant owners and USDA-GIPSA inspection agencies that ... commodities. Testing can take place in a matter of minutes ... the plant test the feed and grain before accepting it, ...
(Date:8/28/2014)... are important devices in spintronics, an electronic which ... electrons but also on their spin and the ... electric into magnetic signals and vice versa. Recently, ... the Institute of Physics at Johannes Gutenberg University ... Prague, and Japan, has for the first time ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3
... Immune Design Corp. (IDC), a privately held biotechnology ... disease, cancer and allergy, announced today that it ... Sanofi-Aventis to investigate the use of IDC,s Glucopyranosyl ... (TLR-4) agonist, in the field of allergy. ...
... 25, 2011 Sangamo BioSciences, Inc. (Nasdaq: SGMO ... For the third quarter ended September 30, ... or $0.18 per share, compared to a net loss of ... in 2010. As of September 30, 2011, the Company had ...
... Graduate Institute (KGI) Research Professor James M. Cregg, PhD, will ... from February 23 – March 3 in Alpbach, Austria. ... development and use of the yeast species, Pichia pastoris ... At the Pichia 2012 Conference he will discuss ...
Cached Biology Technology:Sangamo BioSciences Reports Third Quarter 2011 Financial Results 2Sangamo BioSciences Reports Third Quarter 2011 Financial Results 3Sangamo BioSciences Reports Third Quarter 2011 Financial Results 4Sangamo BioSciences Reports Third Quarter 2011 Financial Results 5Sangamo BioSciences Reports Third Quarter 2011 Financial Results 6KGI Professor Cregg to Be Featured Speaker at Pichia 2012 Conference 2
(Date:8/29/2014)... Scientists at the Barshop Institute for Longevity and Aging ... UT Health Science Center at San Antonio, have found ... longest-lived rodent, the naked mole rat. , They ... mole rats protects and alters the activity of the ... , The factor also protects proteasome function in human, ...
(Date:8/29/2014)... explored the type and number of connections in transcription ... on robustness in a study published in PLOS ... that the assortativity signature contributes to a network,s resilience ... varying the out-out assortativity of TFN models has a ... other three types of assortativity," said Dov A. Pechenick, ...
(Date:8/29/2014)... - In a cell,s nucleus, chromosomal DNA is ... an amalgam biologists call chromatin. Until about two ... "sidekick," the mere packing material around which the ... have developed a greater appreciation for how DNA/histone ... from multiple research institutions studying the sequence of ...
Breaking Biology News(10 mins):Factor in naked mole rat's cells enhances protein integrity 2Assortativity signatures of transcription factor networks contribute to robustness 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3
... two metabolic enzymes, isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2), ... myeloid leukemias (AML). As a result, mutant IDH proteins have ... of adult leukemia. Now a scientific team at Beth ... mouse model of the most common IDH2 mutation in human ...
... the latest in the ocean sciences at the 2014 ... Hotel information, U.S. visa regulations for international reporters ... sciences at the 2014 Ocean Sciences Meeting , ... research findings about the world,s ,oceans at the Ocean ...
... early life experiences may affect food choices in adulthood will ... which includes researchers from the Sahlgrenska Academy. The 7.4 ... out what drives decisions of when we eat and the ... the University of Edinburgh, will examine how eating habits develop ...
Cached Biology News:Animal model demonstrates role for metabolic enzyme in acute myeloid leukemia 2Animal model demonstrates role for metabolic enzyme in acute myeloid leukemia 32014 Ocean Sciences Meeting: Discover the latest in oceanography; press registration open 22014 Ocean Sciences Meeting: Discover the latest in oceanography; press registration open 32014 Ocean Sciences Meeting: Discover the latest in oceanography; press registration open 480 million SEK study seeks to explain what drives our appetites 2
... Microarrays designed for proteomic scale kinase ... and drug discovery research built on the ... platform. These microarrays are available as part ... Peptide Microarray Service. Probe Content ...
... (Ruggedized Advanced Pathogen Identification Device) is ... for field hospitals, mobile laboratories and ... its ruggedness, it is designed with ... the LightCycler instrument. By taking advantage ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... as a carrier in nucleic ... form: Solution in 10 mM ... mM EDTA Preparation Note: Phenol-chloroform ... Concentration: 10 mg/mL Physical ...
Biology Products: